## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($72.20)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. 1 Profitable Stock to Own for Decades and 2 We Find Risky**
- Source: Finviz | 20251201T061100 | Neutral | Relevance: 99%
- This article analyzes one profitable stock to buy and two risky ones to avoid. Hamilton Lane (HLNE) is recommended due to its strong revenue growth and high returns on equity. CooperCompanies (COO) and FactSet (FDS) are identified as risky due to slower growth, declining margins, or underperforming earnings compared to their sectors.

**2. What To Expect From CooperCompaniesâ€™s (COO) Q3 Earnings**
- Source: TradingView | 20251203T050700 | Neutral | Relevance: 99%
- CooperCompanies (COO) is set to announce its Q3 earnings this Thursday afternoon. Analysts expect revenue to grow 4.2% year-on-year to $1.06 billion, with adjusted earnings around $1.12 per share, despite the company having missed revenue estimates four times in the past two years. Peers like Boston Scientific and Stryker have already reported Q3 results, showing positive sentiment in the medical devices & supplies segment, which could hint at CooperCompanies's performance.

**3. Curious about The Cooper Companies (COO) Q4 Performance? Explore Wall Street Estimates for Key Metrics**
- Source: Nasdaq | 20251201T141500 | Neutral | Relevance: 99%
- The Cooper Companies (COO) is projected to report Q4 earnings of $1.11 per share and revenues of $1.06 billion, indicating year-over-year increases. Analysts have revised the EPS estimate downwards by 0.4% in the last 30 days. The article details specific revenue estimates by category and geography, highlighting varied growth expectations across its business segments and regions.

**4. The Cooper Companies Experiences Revision in Stock Evaluation Amid Market Dynamics**
- Source: Markets Mojo | 20251201T160200 | Neutral | Relevance: 98%
- The Cooper Companies, Inc. has undergone a stock evaluation revision due to market fluctuations, with its stock currently at $77.93. The company has experienced significant volatility over the past year, with a high of $106.63 and a low of $61.77. Technical indicators suggest mixed signals, including a mildly bullish sentiment from MACD and KST, while its year-to-date performance lags behind the S&P 500, highlighting ongoing challenges.

**5. What To Expect From CooperCompanies's (COO) Q3 Earnings**
- Source: Finviz | 20251202T220400 | Neutral | Relevance: 98%
- CooperCompanies (NASDAQ:COO) is set to announce its Q3 earnings this Thursday, with analysts expecting a 4.2% year-on-year revenue growth to $1.06 billion and adjusted earnings of $1.12 per share. The medical device company previously met revenue expectations but missed organic revenue estimates last quarter. Sentiment in the medical devices & supplies segment has been positive, with COO stock up 9.3% in the last month.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |
| 2025-12-05 | Stifel | $95 | $85 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |
| 2025-12-05 | Stifel | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-1.1%)
- Blackrock Inc.: 7.7% (-0.8%)
- Capital World Invest: 5.3% (+25.7%)
- T. Rowe Price Invest: 4.9% (+33.2%)
- State Street Corpora: 4.3% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.87 indicates undervaluation relative to growth. Analyst sentiment positive (10 raises, avg +14%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.7B |
| Beta | 1.05 |
| 52W Range | $61.78 - $100.47 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.87 |
| Forward P/E | 15.4 |
| Current P/E | 16.9 |
| YoY Growth | 9.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.2% to -1.9% (-5.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.9pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.90% (CS: 31) | Neutral |
| RSI_14 | 59.8 | Neutral |
| MACD Histogram | 0.31 | Bullish |
| vs SMA20 | 1.035x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.014x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $75.98
- **Stop Loss:** $72.20 (5.0% risk)
- **Target:** $79.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 251
- **Position Value:** $19,070.98
- **Portfolio %:** 19.07%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*